# WD-940

Source: https://onco.cc/drugs/wd-940/  
OnCo record `wd-940` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

WD-940 is an experimental small molecule from Zhejiang Wenda Pharma, in preclinical development for advanced cancer; its current status is not stated.

## Summary

WD-940 is a small molecule from Zhejiang Wenda Pharma. Described only as a brain-penetrant inhibitor of a mutant protein; the company compares it with BI-1810631 and NVL-330 but does not name the target. Its furthest stage is preclinical development, for advanced cancer (unspecified). No clinical trial naming it is registered on ClinicalTrials.gov. The page said WD-940 was expected to enter the clinic in 2024; no registered trial was found on ClinicalTrials.gov. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: WD-940
- Modality: Small molecule
- Mechanism: Described only as a brain-penetrant inhibitor of a mutant protein; the company compares it with BI-1810631 and NVL-330 but does not name the target.

## Sources

- Zhejiang Wenda Pharma: wendapharma.com: https://www.wendapharma.com/pipeline.php
- Zhejiang Wenda Pharma: wendapharma.com: https://www.wendapharma.com/pipeline.php

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Zhejiang Wenda Pharma](https://onco.cc/companies/zhejiang-wenda-pharma/)

---
JSON: https://onco.cc/api/v1/entities/wd-940.json